ArticleJournal of clinical medicine2023
Trends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Advanced Primary Cervical Carcinosarcoma With Ovarian and Peritoneal Metastases in a Premenopausal Woman: A Rare Case Report From Northern Tanzania.Clinical case reports · 2026Article
- Advanced Uterine Carcinosarcoma With Fatal Suspected Pulmonary Embolism in a Resource-Limited Setting: A Rare Case Report.Clinical case reports · 2026Article
- A mouse model of HPV-associated cervicovaginal carcinosarcoma with comparative analysis to human clinical cases.Cell & bioscience · 2026Article
- Models of high-grade serous carcinoma of tubo-ovarian origin.Oncology reviews · 2026Review
- Marital status as an independent prognostic factor for survival in women with vaginal cancer: evidence from the SEER database analysis.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025Observational
- Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma.Gynecologic oncology reports · 2025Article
- Incidence Trends of Vulvar Cancer in the United States: A 20-Year Population-Based Study.Cancer reports (Hoboken, N.J.) · 2024Article
- Malignant mixed mullerian tumors: a SEER database review of rurality and treatment modalities on disease outcome.Frontiers in oncology · 2024Article
- Epidemiology, site-specific characteristics and survival of carcinosarcoma: a retrospective study based on SEER database.BMJ open · 2023Article
- Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinosarcomas (malignant mixed Mullerian tumors) of a female genital organ are rare tumors associated with a poor survival. The purpose of this study was to identify site-specific differences in the incidence and prognosis in carcinosarcomas originating in the uterus, cervix, or ovary. The data of patients with gynecologic carcinosarcomas were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2016. The characteristics of gynecologic carcinosarcomas were compared using Pearson X2 and Fisher's exact tests. Kaplan-Meier models were used for cause-specific survival (CSS) analysis. The cohort included 7086 females, including 5731 cases of uterine carcinosarcoma, 161 cervical carcinosarcomas, and 1193 ovarian carcinosarcomas. The age-adjusted incidence rates of uterine, cervical, and ovarian carcinosarcoma were 3.9, 0.1, and 0.6 per 1,000,000, respectively. In the distribution of carcinosarcoma incidence by race, compared with the uterus or cervix, those originating from the ovary were unequally distributed in Caucasians (84.4% versus 69.6%, 67.7%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.